Fulgent Oncology is part of Fulgent Genetics, a genetic testing company founded in 2011. We were the first clinical laboratory in the U.S. to offer copy number variation (CNV) detection using NGS technology. We've continued to pursue excellence in precision medicine.

By combining our expertise in comprehensive genomic profiling, bioinformatics, artificial intelligence, genetics and pathology, we're making a difference in cancer care by delivering clinically relevant results for better patient outcomes.

We further expanded our capabilities in 2021 through the acquisition of CSI Laboratories, a leader in anatomic pathology and hematology on the East coast with more than 25 years of experience. In 2022, we acquired Inform Diagnostics, a leading anatomic pathology and hematology laboratory on the West coast. As our companies have come together, we've harnessed our collective expertise to create a unique and comprehensive offering.